Luoxin Pharmaceuticals Group Stock Co Ltd
SZSE:002793
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Luoxin Pharmaceuticals Group Stock Co Ltd
Research & Development
Luoxin Pharmaceuticals Group Stock Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Luoxin Pharmaceuticals Group Stock Co Ltd
SZSE:002793
|
Research & Development
-¥101.5m
|
CAGR 3-Years
28%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Research & Development
-¥3.4B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Research & Development
-¥6.7B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-22%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Research & Development
-¥323.2m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-12%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Research & Development
-¥1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-18%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Research & Development
-¥1.4B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
Luoxin Pharmaceuticals Group Stock Co Ltd
Glance View
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 6,393 full-time employees. The company went IPO on 2016-04-15. The firm operates two segments. The Pharmaceutical Industry segment is engaged in the research and development, manufacturing and sales of chemical drug preparations and raw and auxiliary drugs. Its main products are digestive drugs, respiratory drugs and antibiotic drugs, among others. The Pharmaceutical Business segment is engaged in the sales and logistics of agent drugs and medical devices. The firm conducts its businesses in the domestic market.
See Also
What is Luoxin Pharmaceuticals Group Stock Co Ltd's Research & Development?
Research & Development
-101.5m
CNY
Based on the financial report for Sep 30, 2025, Luoxin Pharmaceuticals Group Stock Co Ltd's Research & Development amounts to -101.5m CNY.
What is Luoxin Pharmaceuticals Group Stock Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
22%
Over the last year, the Research & Development growth was -44%. The average annual Research & Development growth rates for Luoxin Pharmaceuticals Group Stock Co Ltd have been 28% over the past three years , 22% over the past five years .
